Clinical Study Featuring Tryton Stent Wins Best Abstract Award at Italian Society of Interventional Cardiology National Congress (GISE) in Genoa, Italy

DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to
definitively treat bifurcation lesions, today announced that an abstract
reporting results from the company’s Tryton stent system was recognized
as the best presented at the Italian Society of Interventional
Cardiology National Congress (GISE) in Genoa, Italy.

The winning abstract was authored by Filippo Russo M.D., Giuseppe de
Nittis, M.D., Elena Butti, M.D., Santo Claudio Zerboni, M.D., Carlo
Campana, M.D., and Mario Galli, M.D., of Ospedale Sant’Anna in Como,
Italy.

The authors conclude that preliminary data suggest that “treatment with
Tryton is safe and associated with good mid-term outcomes; this
technique appears simpler than other ones… and associated with better
results.”

The study enrolled 33 patients with coronary artery disease. The primary
endpoint was achieved in all cases; no patients experienced a major
adverse cardiac event during hospitalization and at 30 days.

“Tryton congratulates Dr. Galli and his colleagues on this winning
abstract,” said J. Greg Davis, president and CEO of Tryton Medical. “We
are pleased that the Tryton Stent System is emerging as the preferred
treatment for bifurcation lesions, as evidenced by the conclusion of the
abstract.”

A live case transmission featuring the Tryton stent in the treatment of
a complex bifurcation lesion performed by Dr. Roberto Bonmassari, M.D.,
of Ospedale Santa Chiara, Trento, went smoothly and was well received by
the more than 400 cardiologist participants.

The Tryton Side Branch Stent System is designed to offer a dedicated
strategy for treating atherosclerotic lesions in the side branch at the
site of a bifurcation. Tryton’s highly deliverable cobalt chromium stent
is deployed in the side branch artery using a standard single-wire
balloon-expandable stent delivery system. A conventional drugeluting
stent is then placed in the main vessel.

The stent system has received CE Mark approval in Europe and is
commercially available in 21 countries throughout Europe and the Middle
East. It is not approved in the United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of
novel stent systems for the treatment of bifurcation lesions. The
company was founded in 2003 by Aaron V. Kaplan, M.D. (Professor of
Medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center)
and Dan Cole to develop stents for the definitive treatment of
bifurcation lesions. The Tryton Side Branch Stent System, approved for
sale in Europe, is designed to offer a dedicated strategy for treating
these challenging cases. Privately held, Tryton is backed by Arnerich
Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest
Ventures. For more information please visit trytonmedical.com.